- Purity and identity checked by HPLC; per-lot COA on request
- Certificate of analysis tied to your lot number
- Tracked EU delivery, dispatched the next working day
Metabolic & Circadian Compounds
SR9011
Synthetic Rev-Erb agonist, an SR9009 analogue, for circadian and metabolic studies
In stock2 formats availableCAS 1379686-29-9
€55Range €55 – €68
This listing is currently unavailable. Contact us and we will tell you when it is back or suggest an equivalent.
Ask about this listing or request its COA- Mol. weight479.04 g/mol
- Research areasCircadian rhythm and sleep architecture, mitochondrial biogenesis, lipid and glucose metabolism, inflammatory signalling, tumour cell viability
For laboratory research use only. Sold exclusively for in-vitro laboratory research by qualified professionals. Not for human or veterinary use, and not a medicine, food, cosmetic or dietary supplement. Terms and Conditions
Overview
Key facts
There is no peptide in SR9011. It is a lab-made small molecule, a sibling of SR9009 from the same chemistry programme in Thomas Burris's group, designed to switch on the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These heme-binding receptors are part of the…
- CAS number
- 1379686-29-9
- Molecular weight
- 479.04 g/mol
- Purity
- HPLC tested for purity and identity; lot-matched COA available
- Storage
- Cool, dry and dark; keep the solution refrigerated and tightly capped
- Available sizes
- 10 mg · 60 capsules · 30 mL liquid · 20 mg/mL
For research use only. Not for human consumption.
There is no peptide in SR9011. It is a lab-made small molecule, a sibling of SR9009 from the same chemistry programme in Thomas Burris's group, designed to switch on the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These heme-binding receptors are part of the circadian clock's central feedback loop, where they suppress the transcription of BMAL1 and of many metabolic genes further down the line.
Both compounds have a pyrrolidine core and a chlorobenzyl-thiophene motif; they differ in the amine groups on the side chain, a change meant to improve pharmacokinetics compared with the earlier lead. In practice the two are usually reported together in the same rodent studies, so the literature on one is hard to interpret without the other.
Research concentrates on what Rev-Erb activation leads to: changes in clock-gene expression, in the amount of mitochondria in skeletal muscle, in how glucose and lipids are processed, in inflammatory signalling by macrophages and, more recently, in whether cancer cell lines survive. That same body of work contains an important caveat, as some effects have been observed in cells that have no Rev-Erb receptors at all. SR9011 is an unapproved research chemical without any medical application and is sold here only for laboratory work.
Specifications
Identity
- CAS number
- 1379686-29-9
- Molecular weight
- 479.04 g/mol
Supply & purity
- Purity
- HPLC tested for purity and identity; lot-matched COA available
Additional detail
- Compound class
- Synthetic small molecule; nuclear receptor (Rev-Erb) agonist — not a peptide
- Molecular targets
- REV-ERBα (NR1D1) and REV-ERBβ (NR1D2)
- Also known as
- SR-9011, SR 9011
- Structural relationship
- Analog of SR9009 (Stenabolic) differing in the side-chain amine substituents
- Available formats
- 10 mg × 60 capsules; 30 mL solution at 20 mg/mL
- Mechanistic role
- Enhances Rev-Erb-mediated transcriptional repression of BMAL1 and downstream metabolic genes
- Research areas
- Circadian rhythm and sleep architecture, mitochondrial biogenesis, lipid and glucose metabolism, inflammatory signalling, tumour cell viability
- Reported pharmacokinetics
- Low oral exposure and short plasma half-life reported in mouse studies
- Regulatory status
- Not an approved medicine; not a dietary supplement; prohibited under the WADA metabolic-modulator category
- Storage
- Cool, dry and dark; keep the solution refrigerated and tightly capped
Questions about SR9011
Does SR9011 belong to the SARMs?
No. SARMs target the androgen receptor, whereas SR9011 activates Rev-Erb nuclear receptors — a completely different pharmacological class, which is why its literature revolves around circadian and metabolic gene expression rather than androgen signalling.
Why is its mechanism disputed?
A 2019 paper showed that SR9009, SR9011's close relative, still produced several of its effects in cells lacking both Rev-Erb receptors — a sign that it can act independently of them. The finding is assumed to apply to this analogue too, so studies nowadays are expected to include Rev-Erb knockout controls.
How do the capsule and liquid formats differ?
The capsules contain a set 10 mg each, so there's nothing to measure; the liquid — 30 mL at 20 mg/mL — is for work that calls for volume-based portions or further dilution. The compound and its lot paperwork are identical in both.
What analytical documentation is available?
Each lot is HPLC-tested for identity and purity, and the lot certificate can be requested. We claim no pharmaceutical-grade certification beyond independent analytical testing; keep the COA with your experimental records.
Related
